The role of p38 mitogen-activated protein kinase in the pathogenesis of inflammatory bowel disease

Journal of Digestive Diseases

Volumn 12, Issue 5, 2011, Pages 327-332

  Feng, Ya Jing ^a   Li, Yong Yu ^a  

^a TONGJI UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Inflammatory bowel disease; MK2; P38 MAPK

Indexed keywords

APOPTOSIS SIGNAL REGULATING KINASE 1; FRACTALKINE; GAMMA INTERFERON; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 11; MITOGEN ACTIVATED PROTEIN KINASE 12; MITOGEN ACTIVATED PROTEIN KINASE 13; MITOGEN ACTIVATED PROTEIN KINASE 14; MITOGEN ACTIVATED PROTEIN KINASE KINASE KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE KINASE KINASE 2; MITOGEN ACTIVATED PROTEIN KINASE KINASE KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE KINASE KINASE 4; MITOGEN ACTIVATED PROTEIN KINASE P38; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR; MIXED LINEAGE KINASE 3; PF 3644022; TRANSFORMING GROWTH FACTOR BETA ACTIVATED KINASE 1; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1;

ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; CARDIOTOXICITY; CD4+ T LYMPHOCYTE; CELL ADHESION; CELL MIGRATION; CELL STRESS; CROHN DISEASE; CYTOKINE PRODUCTION; DRUG ERUPTION; DRUG INDUCED HEADACHE; ENTERITIS; GASTROINTESTINAL SYMPTOM; HELPER CELL; HUMAN; INTRACELLULAR SIGNALING; LEUKOCYTE ACTIVATION; LIVER TOXICITY; LYMPHOCYTE; LYMPHOCYTE ACTIVATION; MACROPHAGE; MYOFIBROBLAST; NEUROTOXICITY; NEUTROPHIL; NONHUMAN; OSMOTIC STRESS; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; ULCERATIVE COLITIS; ULTRAVIOLET RADIATION;

HUMANS; INFLAMMATORY BOWEL DISEASES; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MAP KINASE SIGNALING SYSTEM; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PROTEIN-SERINE-THREONINE KINASES;

EID: 80053412980     PISSN: 17512972     EISSN: 17512980     Source Type: Journal    
DOI: 10.1111/j.1751-2980.2011.00525.x     Document Type: Review

References (35)

1. Baumgart DC, Carding SR. Inflammatory bowel disease: cause and immunobiology. Lancet 2007; 369: 1627-40.
2. Hommes D, van den Blink B, Plasse T etal.Inhibition of stress-activated MAP kinases induces clinical improvement in moderate to severe Crohn's disease. Gastroenterology 2002; 122: 7-14.
3. ten Hove T, van den Blink B, Pronk I, Drillenburg P, Peppelenbosch MP, van Deventer SJ. Dichotomal role of inhibition of p38 MAPK with SB 203580 in experimental colitis. Gut 2002; 50: 507-12.
4. van Montfrans C, Peppelenbosch M, te Velde AA, van Deventer S. Inflammatory signal transduction in Crohn's disease and novel therapeutic approaches. Biochem Pharmacol 2002; 64: 789-95.
5. Li J, Campanale NV, Liang RJ, Deane JA, Bertram JF, Ricardo SD. Inhibition of p38 mitogen-activated protein kinase and transforming growth factor-beta1/Smad signaling pathways modulates the development of fibrosis in adriamycin-induced nephropathy. Am J Pathol 2006; 169: 1527-40.
6. Scaldaferri F, Correale C, Gasbarrini A, Danese S. Molecular signaling blockade as a new approach to inhibit leukocyte-endothelial interactions for inflammatory bowel disease treatment. Cell Adh Migr 2009; 3: 296-9.
7. Fiocchi C. Intestinal inflammation: a complex interplay of immune and nonimmune cell interactions. Am J Physiol 1997; 273: G769-75.
8. Kidd M, Gustafsson BI, Drozdov I, Modlin IM. IL1beta- and LPS-induced serotonin secretion is increased in EC cells derived from Crohn's disease. Neurogastroenterol Motil 2009; 21: 439-50.
9. Di Mari JF, Saada JI, Mifflin RC, Valentich JD, Powell DW. HETEs enhance IL-1-mediated COX-2 expression via augmentation of message stability in human colonic myofibroblasts. Am J Physiol Gastrointest Liver Physiol 2007; 293: G719-28.
10. Danese S, Semeraro S, Marini M etal. Adhesion molecules in inflammatory bowel disease: therapeutic implications for gut inflammation. Dig Liver Dis 2005; 37: 811-18.
11. Dambach DM. Potential adverse effects associated with inhibition of p38alpha/beta MAP kinases. Curr Top Med Chem 2005; 5: 929-39.
12. Kyriakis JM, Avruch J. Mammalian mitogen-activated protein kinase signal transduction pathways activated by stress and inflammation. Physiol Rev 2001; 81: 807-69.
13. Schindler JF, Monahan JB, Smith WG. p38 pathway kinases as anti-inflammatory drug targets. J Dent Res 2007; 86: 800-11.
14. Kuma Y, Sabio G, Bain J, Shpiro N, Marquez R, Cuenda A. BIRB796 inhibits all p38 MAPK isoforms in vitro and in vivo. J Biol Chem 2005; 280: 19472-9.
15. Remy G, Risco AM, Inesta-Vaquera FA etal. Differential activation of p38MAPK isoforms by MKK6 and MKK3. Cell Signal 2010; 22: 660-7.
16. Thalhamer T, McGrath MA, Harnett MM. MAPKs and their relevance to arthritis and inflammation. Rheumatology (Oxford) 2008; 47: 409-14.
17. Ronkina N, Kotlyarov A, Dittrich-Breiholz O etal. The mitogen-activated protein kinase (MAPK)-activated protein kinases MK2 and MK3 cooperate in stimulation of tumor necrosis factor biosynthesis and stabilization of p38 MAPK. Mol Cell Biol 2007; 27: 170-81.
18. Broom OJ, Widjaya B, Troelsen J, Olsen J, Nielsen OH. Mitogen activated protein kinases: a role in inflammatory bowel disease? Clin Exp Immunol 2009; 158: 272-80.
19. Duraisamy S, Bajpai M, Bughani U, Dastidar SG, Ray A, Chopra P. MK2: a novel molecular target for anti-inflammatory therapy. Expert Opin Ther Targets 2008; 12: 921-36.
20. Kostenko S, Moens U. Heat shock protein 27 phosphorylation: kinases, phosphatases, functions and pathology. Cell Mol Life Sci 2009; 66: 3289-307.
21. Fuss IJ, Neurath M, Boirivant M etal. Disparate CD4+ lamina propria (LP) lymphokine secretion profiles in inflammatory bowel disease. Crohn's disease LP cells manifest increased secretion of IFN-gamma, whereas ulcerative colitis LP cells manifest increased secretion of IL-5. J Immunol 1996; 157: 1261-70.
22. Himmel ME, Hardenberg G, Piccirillo CA, Steiner TS, Levings MK. The role of T-regulatory cells and Toll-like receptors in the pathogenesis of human inflammatory bowel disease. Immunology 2008; 125: 145-53.
23. Scaldaferri F, Sans M, Vetrano S etal. The role of MAPK in governing lymphocyte adhesion to and migration across the microvasculature in inflammatory bowel disease. Eur J Immunol 2009; 39: 290-300.
24. Mahida YR. The key role of macrophages in the immunopathogenesis of inflammatory bowel disease. Inflamm Bowel Dis 2000; 6: 21-33.
25. Saklatvala J, Dean J, Clark A. Control of the expression of inflammatory response genes. Biochem Soc Symp 2003; 70: 95-106.
26. Winston BW, Chan ED, Johnson GL, Riches DW. Activation of p38mapk, MKK3, and MKK4 by TNF-alpha in mouse bone marrow-derived macrophages. J Immunol 1997; 159: 4491-7.
27. Kotlyarov A, Neininger A, Schubert C etal. MAPKAP kinase 2 is essential for LPS-induced TNF-alpha biosynthesis. Nat Cell Biol 1999; 1: 94-7.
28. Li YY, Ochs S, Gao ZR etal. Regulation of HSP60 and the role of MK2 in a new model of severe experimental pancreatitis. Am J Physiol Gastrointest Liver Physiol 2009; 297: G981-9.
29. Tietz AB, Malo A, Diebold J etal. Gene deletion of MK2 inhibits TNF-alpha and IL-6 and protects against cerulein-induced pancreatitis. Am J Physiol Gastrointest Liver Physiol 2006; 290: G1298-306.
30. Mudgett JS, Ding J, Guh-Siesel L etal. Essential role for p38alpha mitogen-activated protein kinase in placental angiogenesis. Proc Natl Acad Sci USA 2000; 97: 10454-9.
31. Williams DE, Telliez JB, Liu J, Tahir A, van Soest R, Andersen RJ. Meroterpenoid MAPKAP (MK2) inhibitors isolated from the Indonesian marine sponge Acanthodendrilla sp. J Nat Prod 2004; 67: 2127-9.
32. Anderson DR, Hegde S, Reinhard E etal. Aminocyanopyridine inhibitors of mitogen activated protein kinase-activated protein kinase 2 (MK-2). Bioorg Med Chem Lett 2005; 15: 1587-90.
33. Anderson DR, Meyers MJ, Vernier WF etal. Pyrrolopyridine inhibitors of mitogen-activated protein kinase-activated protein kinase 2 (MK-2). J Med Chem 2007; 50: 2647-54.
34. Mourey RJ, Burnette BL, Brustkern SJ etal. A benzothiophene inhibitor of mitogen-activated protein kinase-activated protein kinase 2 inhibits tumor necrosis factor alpha production and has oral anti-inflammatory efficacy in acute and chronic models of inflammation. J Pharmacol Exp Ther 2010; 333: 797-807.
35. Coxon PY, Rane MJ, Uriarte S etal. MAPK-activated protein kinase-2 participates in p38 MAPK-dependent and ERK-dependent functions in human neutrophils. Cell Signal 2003; 15: 993-1001.